DESIGN AND SYNTHESIS OF SOME NEWER IMIDAZOLYL HETEROCYCLES AS POTENT BTK INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
DOI:
https://doi.org/10.22159/ijcpr.2017.v9i3.19668Keywords:
Rheumatoid arthritis, Molecular docking, ADMET properties, BTK inhibitors, Pharmacophore model, NilAbstract
Objective: The rheumatoid arthritis as a global health problem over the past few decades, Emphasizes the need for discovery of new therapeutic disease modifying anti-rheumatoid Arthritis drugs (DMARD's). Bruton's tyrosine kinase (BTK) is a cytoplasmic, non-receptor, tyrosine kinase which is expressed in most of the hematopoietic cells and plays an important role in the development, differentiation and proliferation of B-lineage cells, thus making BTK an efficient therapeutic target for the treatment of rheumatoid arthritis. This prompted us to synthesise a novel series of Imidazolyl Heterocycles as potent BTK (Bruton's Tyrosine Kinase) inhibitors with alleged Anti-Rheumatoid Arthritis properties.
Methods: Newer BTK inhibitors containing one hydrogen bond acceptor (HBA), one hydrogen bond donor (HBD) and three hydrophobic features based on that pharmacophore model for BTK were designed. The designed compounds were sorted by applying ADMET properties, Lipinski rule of five, molecular docking and Novelty prediction to refine the designed ligands. Finally, different five compounds containing Imidazole as the heterocyclic nucleus have been synthesized and characterized by different analytical methods like Chromatographic data, Elemental analysis and Spectral studies by IR, 1H NMR, 13C NMR, GC-MS. Molecular docking studies were performed against BTK using GLIDE 10.2.
Results: Several important hydrogen bonds with BTK were revealed, which include the gatekeeper residue Glu475 and Met477 at the hinge region.
Conclusion: Overall, this study suggests that the proposed ligands are found to be more effective BTK inhibitor as Anti-Rheumatoid arthritis agents.
Downloads
References
Smolen JS, Steiner G, Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discovery 2003;2:473–88.
Van Doornum S, Jennings GL, Wicks IP. Reducing the cardiovascular disease burden in rheumatoid arthritis. Med J Aust 2006;184:287–90.
Satterthwaite AB, Witte ON. The role of Bruton’s tyrosine kinase in B-cell development and function a genetic perspective. Immunol Rev 2000;175:120–7.
Niiro H, Clark EA. Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2002;2:945–56.
Chang BY, Huang MM, Francesco M, Chen J, Sokolove J, Magadala P. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Research and Therapy 2011;13:R115.
Aalipour A, Advani RH. Bruton’s tyrosine kinase inhibitors: a promising novel targeted treatment for B-cell lymphomas. Br J Haematol 2013;163:436–43.
Gomperts BD, Kramer IM, Tatham PER. Tyrosine protein kinases and adaptive immunity: TCR, BCR, soluble tyrosine kinases and NFAT In Signal transduction, San Diego: 2ndedn. Academic Press: 2009. p. 513-42.
Reproduced with permission from Elseivier, This table was published in Signal Transduction. 2nd edn. Copyright Elsevier www. rheumatology. oxford journals. Org; 2009.
Miller MW, Howe Jr HL, Kasubick RV, English AR. European Journal of Medicinal Chemistry; 1970. p. 840.
Prajapati NK, Asha D Patel, Jignesh A Patel, Prajapati SP. Coordination polymers of N,N’-Di-(8-Hydroxyquinolinolyl-5-Methyl)-N,N’-Diethyl-1,4-But-2-Enediamine (QEBD). Int J Chem Sci 2011;9:363-70.
Gajrajsharma GM, Sreenivasa E, Jayachandran. Synthesis of bioactive molecule fluoro benzothiazole comprising quinazolinyl-oxazoles derivative for biological and pharmacological screening. Int J Chem 2009;7:1379-94.
Bavi R, Kumar R, Choi L, Woo Lee K. Exploration of Novel inhibitors for bruton’s tyrosine kinase by 3d qsar modeling and molecular dynamics simulation. PLoS One 2016;11:7.
Published
How to Cite
Issue
Section
